Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Gains from Sales and Divestitures (2021 - 2025)

Historic Gains from Sales and Divestitures for Journey Medical (DERM) over the last 5 years, with Q3 2025 value amounting to $927446.0.

  • Journey Medical's Gains from Sales and Divestitures rose 375.27% to $927446.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $927446.0, marking a year-over-year increase of 375.27%. This contributed to the annual value of $1.1 million for FY2024, which is 4553.12% up from last year.
  • As of Q3 2025, Journey Medical's Gains from Sales and Divestitures stood at $927446.0, which was up 375.27% from $324159.0 recorded in Q2 2025.
  • Journey Medical's Gains from Sales and Divestitures' 5-year high stood at $1.1 million during Q4 2024, with a 5-year trough of $2000.0 in Q1 2022.
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $287951.0 (2022), whereas its average is $395161.2.
  • In the last 5 years, Journey Medical's Gains from Sales and Divestitures soared by 333310.0% in 2023 and then crashed by 7610.7% in 2025.
  • Journey Medical's Gains from Sales and Divestitures (Quarter) stood at $136500.0 in 2021, then soared by 115.17% to $293707.0 in 2022, then surged by 147.61% to $727249.0 in 2023, then skyrocketed by 45.53% to $1.1 million in 2024, then dropped by 12.37% to $927446.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $927446.0 for Q3 2025, versus $324159.0 for Q2 2025 and $50421.0 for Q1 2025.